A Phase 4 interventional study of Cilostazol and Clopidogrel in Ischemic Stroke and TIA, sponsored by Incheon St.Mary's Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-08-06.
Sponsored by Incheon St.Mary's Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing cilostazol in Ischemic Stroke — 9 open to participants now, 9 under way, 7 of them phase 3. Cilostazol · Ischemic Stroke.
Among the 18 studies testing cilostazol in Ischemic Stroke, this one is the 16th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 4, and was the 11th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →9 of the 18 studies testing cilostazol in Ischemic Stroke are open now, in 3 countries. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 40+
Second Affiliated Hospital of Soochow University · Sites in China
Ages 18–80
Kafrelsheikh University · Sites in Egypt
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
Kafrelsheikh University · Sites in Egypt
Ages 18–75
By country, each count listing its studies:
Cilostazol: first FDA approval 1999 (PLETAL). What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 378 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 848 across the 18 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 9 most frequent:
Incheon St.Mary's Hospital is the lead sponsor of 20 studies on the registry; 4 are open to participants now.
Incheon St.Mary's Hospital has 2 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing cilostazol in Ischemic Stroke, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, open-labelled trial. We randomly assigned patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with cilostazol and aspirin or to clopidogrel plus aspirin. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis.
This study is a randomized, open-labelled trial. We randomly assigned patients within 24 hours after the onset of minor ischemic stroke or high-risk TIA to combination therapy with cilostazol and aspirin (aspirin 100mg with cilostazol 200 mg for 21 days) or to clopidogrel plus aspirin (aspirin 100mg with clopidogrel 75mg for 21 days). The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. The primary safety outcome was the moderate-to-severe bleeding event according to (GUSTO) definition. The secondary outcomes were new clinical vascular event (ischemic or hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes. Vascular death was defined as death due to stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
aspirin 100mg with clopidogrel 75mg for 21 days
Drug: Clopidogrel
aspirin 100mg with cilostazol 200 mg for 21 days
Drug: Cilostazol
patients were given cilostazol 100mg twice a day with aspirin
Also known as: aspirin
patients were given clopidogrel 75mg with aspirin
Also known as: aspirin
New stroke event for 90 days (Ischemic or hemorrhagic)
New stroke event for 90 days (Ischemic or hemorrhagic)
Time frame: for 90 days
Moderate-to-severe bleeding event according to (GUSTO) definition
Moderate-to-severe bleeding event according to (GUSTO) definition: Moderate : bleeding requiring transfusion Severe : Fatal or intracerebral bleeding, or bleeding resulting in substantial hemodynamic compromise requiring treatment
Time frame: for 90 days
New clinical vascular event (ischemic or hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes.
New clinical vascular event (ischemic or hemorrhagic stroke, myocardial infarction, or vascular death), analyzed as a composite outcome and also as individual outcomes. Vascular death was defined as death due to stroke (ischemic or hemorrhagic), systemic hemorrhage, myocardial infarction, congestive heart failure, pulmonary embolism, sudden death, or arrhythmia.
Time frame: for 90 days
Ran from Jul 2019 to primary completion in Oct 2022, 38 months.
Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's 38 months is above that.
Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cilostazol
Incheon St.Mary's Hospital